TIDMRGT 
 
ReGen appoints ICUK to assist developments in China 
 
17 June 2010 
 
ReGen Therapeutics Plc ('ReGen' or the 'Company') <AIM: RGT> has appointed 
Innovation China UK ('ICUK') to assist in discussions with a major 
pharmaceutical company in China, which the Company hopes will lead to the 
establishment of ReGen's business in this growing and important healthcare 
market.  ICUK is a publicly funded programme established to support joint 
innovation and technology transfer between the UK and China. 
 
ReGen was assisted by the Chinese team at its broker Alexander David Securities 
with initial contacts in the Chinese market.  It was apparent from these 
contacts that ReGen required the assistance of a well-respected and strong 
advisor, based both in the UK and China, to take our Chinese project further. 
ICUK fitted these criteria, having previously used its expertise to open initial 
discussions with a major Chinese pharmaceutical company, which then led to a 
confidentiality agreement being signed between the company and ReGen. We have 
now formally engaged ICUK to work actively on our behalf to assist with detailed 
negotiations e.g. preparing a presentation in Chinese and going to China to talk 
to relevant personnel in the target company.  ReGen believes that ICUK will be 
crucial in bringing the deal to fruition in this major market. 
 
Manyi Cristofoil - Executive Director of ICUK commented: 
 
'We are excited about the opportunity to assist ReGen to develop a Chinese 
market for its products.  With over 23 per cent of Chinese people expected to be 
over the age of 65 by 2020 and with their ability to purchase clinically-proven 
nutritional supplements steadily increasing, Colostrinin(TM) will have a 
potentially significant market in China when ReGen secures its distribution 
through an established local partner.' 
 
Through its wide networks in China, ICUK offers consultancy services to both UK 
and Chinese companies and research organisations on cross boundary knowledge 
transfer, business partnering and technology commercialisation.  This 
consultancy service will be provided to ReGen Therapeutics Plc by the ICUK 
programme office at Queen Mary Innovation Limited, a technology transfer company 
wholly owned by Queen Mary, University of London. 
 
For further information, please contact: 
 
Percy Lomax 
ReGen Therapeutics Plc 
Tel: 020 7153 4920 
 
Roland Cornish/Felicity Geidt 
Beaumont Cornish Limited 
Tel: 020 7628 3396 
 
David Scott/Nick Bealer 
Alexander David Securities Limited 
Tel: 020 7448 9820 
Note to Editors: 
 
The Chinese healthcare market 
 
AstraZeneca, the second largest British drug company, had sales in China of 
 GBP550m last year and believes the market is growing at 30% per annum.  China has 
just announced a healthcare reform package and is putting $125bn into 
healthcare.  The combined impact of China's population, economic growth and 
development of healthcare makes this one of the top three target markets for 
ReGen. 
 
About ReGen and Colostrinin(TM) 
 
ReGen Therapeutics Plc was formed in February 1998 to develop Colostrinin(TM), a 
proline-rich polypeptide complex derived from mammalian colostrum. 
Colostrinin(TM) is promoted as a support for healthy brain ageing and 
cognition.  Peptides derived from Colostrinin(TM) are viewed as having potential 
in the treatment of neurodegenerative illnesses such as Alzheimer's disease, 
Parkinson's Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis. 
 
The Company is rolling out Colostrinin(TM) as a nutraceutical product in a 
growing number of countries worldwide.  Since 2006, the Company has signed deals 
with several independent distributors to commercialise Colostrinin(TM) under 
various brand names. The product has been available in North America and 
Australasia since 2007, in Cyprus and in Poland and the United Kingdom since 
2009. So far in 2010, Colostrinin(TM) is being launched in Turkey and India. 
ReGen continues to negotiate arrangements for other regions and further details 
of each of the distributors can be found in the Products & Research section of 
the ReGen website -www.regentherapeutics.com <http://www.regentherapeutics.com/> 
 
 
 
 
[HUG#1424521]
Argent Biopharma (LSE:RGT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Argent Biopharma Charts.
Argent Biopharma (LSE:RGT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Argent Biopharma Charts.